| 000 | 01870 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250516165717.0 | ||
| 264 | 0 | _c20140929 | |
| 008 | 201409s 0 0 eng d | ||
| 022 | _a1875-533X | ||
| 024 | 7 |
_a10.2174/09298673113209990238 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSilvestris, Nicola | |
| 245 | 0 | 0 |
_aTarget therapies in pancreatic carcinoma. _h[electronic resource] |
| 260 |
_bCurrent medicinal chemistry _c2014 |
||
| 300 |
_a948-65 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAlbumins _xtherapeutic use |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xtherapeutic use |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 | _aBevacizumab |
| 650 | 0 | 4 |
_aErbB Receptors _xantagonists & inhibitors |
| 650 | 0 | 4 | _aErlotinib Hydrochloride |
| 650 | 0 | 4 |
_aHedgehog Proteins _xantagonists & inhibitors |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMatrix Metalloproteinases _xmetabolism |
| 650 | 0 | 4 |
_aMolecular Targeted Therapy _xmethods |
| 650 | 0 | 4 |
_aPaclitaxel _xtherapeutic use |
| 650 | 0 | 4 |
_aPancreas _xdrug effects |
| 650 | 0 | 4 |
_aPancreatic Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aQuinazolines _xtherapeutic use |
| 650 | 0 | 4 |
_aReceptor, IGF Type 1 _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aSignal Transduction _xdrug effects |
| 700 | 1 | _aGnoni, Antonio | |
| 700 | 1 | _aBrunetti, Anna Elisabetta | |
| 700 | 1 | _aVincenti, Leonardo | |
| 700 | 1 | _aSantini, Daniele | |
| 700 | 1 | _aTonini, Giuseppe | |
| 700 | 1 | _aMerchionne, Francesca | |
| 700 | 1 | _aMaiello, Evaristo | |
| 700 | 1 | _aLorusso, Vito | |
| 700 | 1 | _aNardulli, Patrizia | |
| 700 | 1 | _aAzzariti, Amalia | |
| 700 | 1 | _aReni, Michele | |
| 773 | 0 |
_tCurrent medicinal chemistry _gvol. 21 _gno. 8 _gp. 948-65 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2174/09298673113209990238 _zAvailable from publisher's website |
| 999 |
_c23047637 _d23047637 |
||